Label–Cap Combination From Schreiner MediPharm Prevents Counterfeiting - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Label–Cap Combination From Schreiner MediPharm Prevents Counterfeiting
The Flexi-Cap features a first-opening indication as an anticounterfeiting solution.

Equipment and Processing Report

Schreiner MediPharm's Flexi-Cap label-and-cap combination features a first-opening indication that prevents the illegal reuse of medicine containers under the guise of being unopened, original products. Flexi-Cap comprises a label combined with a cap that gives a clear and irreversible indication that a primary container has been opened. The technology is similar to the cover for wine bottles but adapted to the specific requirements of the pharmaceutical industry.

To use Flexi-Cap, the film cap is positioned over the closed container, and the label is applied without covering the peel-open tab of the opening strip. Once the strip is opened, the bottom part of the cap, together with the label, remains attached to the container. Attempting to remove the rest of the cap destroys the label, thus eliminating the possibility of unnoticed illegal reuse.

Flexi-Cap enables flexible use with different container types, forms, and sizes. In contrast to shrink-wrap solutions, the label construction can be applied without using heat, making the solution viable for temperature-sensitive medicines. The pharmaceutical manufacturer's label and brand design remain unchanged, due to the combination of label and cap. In addition, the top of the cap allows space for bar code printing or chip integration for electronic tracking.

Source: Schreiner MediPharm

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Equipment and Processing Report,
Click here